Georgia sells ESPR 35.09: Finally, Credit Suisse initiated coverage on shares of Esperion Therapeutics in a research report on Thursday, June 25th.

Citigroup Inc. reissued a buy rating and set a $120.00 target price (down previously from $130.00) on shares of Esperion Therapeutics in a research report on Monday, July 27th. Stifel Nicolaus raised their price objective on shares of Esperion Therapeutics from $106.00 to $116.00 and gave the company a buy rating in a report on Friday, May 8th. FIX reissued an add rating on shares of Esperion Therapeutics in a report on Monday, August 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Finally, JMP Securities increased their price target on Esperion Therapeutics from $121.00 to $177.00 and gave the company an outperform rating in a report on Wednesday, June 3rd.


Alex:
Chardan Capital initiated coverage on Esperion Therapeutics in a research report on Friday, May 22nd.

Jazmine:
They issued an outperform rating and a $150.00 target price for the company.

Teresia:
RBC Capital initiated coverage on Esperion Therapeutics in a research note on Wednesday, April 22nd.

Rosemary:
Esperion Therapeutics ( NASDAQ:ESPR ) opened at 54.47 on Tuesday.

Mathilde:
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 6th.

Judith:
One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company.

Kindra:
They set an overweight rating and a $150.00 price objective for the company.

Sandra:
Finally, Barclays began coverage on Esperion Therapeutics in a research note on Thursday, May 21st.

Cleotilde:
Needham & Company LLC upped their price objective on shares of Esperion Therapeutics from $104.00 to $130.00 and gave the stock a buy rating in a research report on Friday, May 8th.

Betsey:
They set an outperform rating and a $150.00 price objective on the stock.

Esperion Therapeutics (NASDAQ:ESPR)
//stockhand.net/us/?q=nasdaq%3Aespr&id=295350